Multicenter Investigation of Xanthine Oxidase Inhibitor Efficacy for CKD patients with Hyperuricemia

Multicenter Investigation of Xanthine Oxidase Inhibitor Efficacy for CKD patients with Hyperuricemia - MIE-CKD study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016172

Enrollment

100

Registered

2015-01-12

Start date

2015-01-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

topiroxostat febuxostat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: serum uric acid ;7.0mg/dl eGFR 15-60ml/min urine protein creatinine ratio 0.15-3.5g/gCr

Exclusion criteria

Exclusion criteria: gout attack within 4 weeks obstructive uropathy primary hyperuricemia use xanthine oxidase inhibitor within 4 weeks malignant disease

Design outcomes

Primary

Measure	Time frame
urine protein	—

Countries

Japan

Contacts

Public ContactHiroshi Matsuo

Suzuka Kaisei Hospital Nephrology and Dialysis

hmatsuo.16@gmail.com059-375-1212

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026